Literature DB >> 20071176

Gamma knife radiosurgery for growth hormone-producing adenomas.

Yoshiyasu Iwai1, Kazuhiro Yamanaka, Masaki Yoshimura, Isao Kawasaki, Keiko Yamagami, Katsunobu Yoshioka.   

Abstract

We evaluated the endocrinological outcomes of gamma knife radiosurgery (GKS) for the treatment of growth hormone (GH)-producing pituitary adenomas. Twenty-six patients treated with GKS (median treatment [tumour] volume: 0.8 mL; median marginal radiation dose: 20Gy) were followed for a median of 84 months. "Disease remission" was defined as either nadir levels of GH <1 microg/L during an oral glucose load, or random GH levels <2 microg/L and normal age-adjusted and sex-adjusted levels of insulin-like growth factor without pituitary suppressive medications. The remission rate was 38% (10/26) and the 5-year and 10-year actuarial remission rates were 16.9% and 47.4%, respectively. Two patients (8%) suffered hypopituitarism requiring medication, but no other serious deficits were observed. Although GKS requires a relatively long time to achieve hormonal remission, it is a very useful, long-term treatment for GH-producing adenomas. We propose that compared to continuing life-long medication, GKS is less invasive and more cost effective. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071176     DOI: 10.1016/j.jocn.2009.05.040

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  12 in total

1.  Gamma knife radiosurgery for clinically persistent acromegaly.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

Review 2.  Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy.

Authors:  Dale Ding; Robert M Starke; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-05       Impact factor: 4.130

Review 3.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

Review 5.  Cranial stereotactic radiosurgery: current status of the initial paradigm shifter.

Authors:  Jason P Sheehan; Chun-Po Yen; Cheng-Chia Lee; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 6.  Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.

Authors:  Dale Ding; Chun-Po Yen; Robert M Starke; Cheng-Chia Lee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-08-14       Impact factor: 4.130

Review 7.  Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Enrico Clarke; Claudia Scaringi; Riccardo Maurizi Enrici
Journal:  Rep Pract Oncol Radiother       Date:  2014-10-14

8.  Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas.

Authors:  Won Kim; Claire Clelland; Isaac Yang; Nader Pouratian
Journal:  Surg Neurol Int       Date:  2012-04-26

Review 9.  Radiation techniques for acromegaly.

Authors:  Giuseppe Minniti; Claudia Scaringi; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2011-12-02       Impact factor: 3.481

10.  Stereotactic Irradiation of GH-Secreting Pituitary Adenomas.

Authors:  G Minniti; C Scaringi; D Amelio; R Maurizi Enrici
Journal:  Int J Endocrinol       Date:  2012-02-22       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.